Ascentage Pharma
800 King Farm Blvd.
Suite 300
Rockville
MD
20850
United States
Website: http://www.ascentagepharma.com/
162 articles about Ascentage Pharma
-
AACR 2024 | Ascentage Pharma Presents Results from Three Studies at 2024 American Association of Cancer Research Annual Meeting
4/8/2024
Ascentage Pharma announced that it releases the latest results from three preclinical studies of its novel drug candidates olverembatinib, MDM2-p53 inhibitor alrizomadlin, FAK/ALK/ROS1 tyrosine kinase inhibitor APG-2449, and embryonic ectoderm development inhibitor APG-5918, at the 2024 American Association of Cancer Research Annual Meeting.
-
Ascentage Pharma Announces 2023 Annual Results
3/27/2024
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its annual results for the full year 2023.
-
AACR 2024 | Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting
3/6/2024
Ascentage Pharma announced that the latest results from three preclinical studies of the company's novel drug candidates olverembatinib, MDM2-p53 inhibitor alrizomadlin, FAK/ALK/ROS1 tyrosine kinase inhibitor APG-2449, and EED inhibitor APG-5918, have been selected for presentations at the 2024 American Association of Cancer Research Annual Meeting.
-
Global Registrational Phase III Study of Olverembatinib (HQP1351) Cleared by FDA
2/14/2024
Ascentage Pharma announced that it has received clearance from the US Food and Drug Administration to initiate a global registrational Phase III trial of olverembatinib in previously treated adult patients with chronic-phase chronic myeloid leukemia.
-
Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia (CML) Management from the National Comprehensive Cancer Network (NCCN)
1/17/2024
Ascentage Pharma announced that olverembatinib has been included in the latest guidelines from the National Comprehensive Cancer Network for the management of Chronic Myeloid Leukemia,[1] marking a major development in global recognition for its best-in-class drug candidate, which has been approved in China for the management of tyrosine kinase inhibitor -resistant patients with chronic- and accelerated-phase CML.
-
Ascentage Pharma Presented at 42nd Annual J.P. Morgan Healthcare Conference
1/11/2024
Ascentage Pharma announced that Dr. Dajun Yang, the company's Chairman and CEO, gave a speech at the 42nd Annual J.P. Morgan Healthcare Conference.
-
Ascentage Pharma to Present at 42nd J.P. Morgan Healthcare Conference
1/2/2024
Ascentage Pharma announced that it will attend the 42nd J.P. Morgan Healthcare Conference, and Dr. Dajun Yang, its Chairman and CEO, will give a presentation on Ascentage Pharma at the conference at 2:00 AM, Thursday, January 11, 2024, Beijing Time.
-
Live from ASH 2023 | Oral Report Featuring Encouraging Data of Olverembatinib Combined with Reduced-Intensity Chemotherapy in Patients with Ph+ ALL Presented at the ASH Annual Meeting
12/15/2023
Ascentage Pharma announced that Prof. Xiaoyuan Gong has presented the preliminary results from a Phase II study of Ascentage Pharma's novel drug candidate, olverembatinib, combined with reduced-intensity chemotherapy in treatment-naïve patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, in an Oral Report at the 65th American Society of Hematology Annual Meeting, taking place in San Diego, CA, the United States.
-
Live from ASH 2023 | Ascentage Pharma Presents the First Dataset of Bcl-2 inhibitor Lisaftoclax in Patients with AML, Demonstrating Favorable Efficacy and Safety
12/12/2023
Ascentage Pharma announced that it has released the results of lisaftoclax, one of the company's key drug candidates, in patients with treatment-naïve or relapsed/refractory acute myeloid leukemia or other myeloid neoplasms, in a Poster Presentation at the 65th American Society of Hematology Annual Meeting, taking place in San Diego, CA, the United States.
-
Live from ASH 2023 | Ascentage Pharma Presents Updated Data from US Study of Olverembatinib, Further Validating Encouraging Efficacy in Patients Resistant to Ponatinib or Asciminib
12/11/2023
Ascentage Pharma announced that it has released updated data from a US study of the company's novel drug candidate, olverembatinib, in patients with refractory chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, in a Poster Presentation at the 65th American Society of Hematology Annual Meeting, taking place in San Diego, CA, the United States.
-
Live from ASH 2023 | Ascentage Pharma Releases Encouraging Long-Term Data of Bcl-2 Inhibitor Lisaftoclax in R/R CLL, Including an ORR of 73.3%
12/11/2023
Ascentage Pharma announced that it has released the latest efficacy and safety data of lisaftoclax, one of the company's key drug candidates, in patients with heavily pretreated chronic lymphocytic leukemia, in a Poster Presentation at the 65th American Society of Hematology Annual Meeting, taking place in San Diego, CA, the United States.
-
Ascentage Pharma Hosts Ceremony Marking the Launch of Olverembatinib in Newly Approved Indication and the Dispatch of First Batch for the New Indication
11/24/2023
Ascentage Pharma hosted a ceremony in Suzhou, China, marking the launch of olverembatinib in a newly approved indication and the dispatch of the first batch of the drug for the new indication.
-
ASH 2023 | For the Sixth Consecutive Year, Results from Multiple Clinical Studies of Olverembatinib Have Been Selected for Presentations, Including Two Oral Reports, at the 2023 ASH Annual Meeting
11/3/2023
Ascentage Pharma announced that results from multiple clinical studies of the company's novel drug candidate, olverembatinib, have been selected for presentations, including two Oral Reports, at the 65th American Society of Hematology Annual Meeting.
-
ASH 2023 | Ascentage Pharma to Present Results from Three Clinical Studies of Bcl-2 Inhibitor Lisaftoclax (APG-2575), Including the First Data in AML and MM
11/3/2023
Ascentage Pharma announced that results from three clinical studies of lisaftoclax, a key candidate drug in the Company's pipeline, have been selected for presentations at the 65th American Society of Hematology Annual Meeting, marking the second consecutive year in which clinical results of lisaftoclax were selected.
-
Live from ESMO 2023 | Oral Report Featuring Latest Data of Pelcitoclax (APG-1252) Combined with Osimertinib Demonstrates Potential as a New Treatment Option for TP53-and EGFR-Mutant NSCLC
10/23/2023
Ascentage Pharma (6855.HK) announced today that it has released the latest clinical data of its dual Bcl-2/Bcl-xL inhibitor, APG-1252 (pelcitoclax), combined with osimertinib for the treatment of patients with EGFR-mutant non-small cell lung cancer (NSCLC) in a Mini Oral at the 2023 European Society of Medical Oncology (ESMO) Congress.
-
First Patient Dosed in the Registrational Phase III Study of Olverembatinib in Treatment-Naïve Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
10/18/2023
Ascentage Pharma announced that the registrational Phase III study of olverembatinib, Ascentage Pharma's lead drug candidate, combined with chemotherapy, versus imatinib combined with chemotherapy in treatment-naïve patients with Philadelphia chromosome-positive acute lymphoblastic leukemia has dosed its first patient.
-
Ascentage Pharma and AstraZeneca Enter into Clinical Collaboration on the Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Combination with BTK Inhibitor Acalabrutinib in Treatment-Naïve Patients with First-Line CLL/SLL
10/16/2023
Ascentage Pharma announced that it has entered into a clinical collaboration with AstraZeneca Investment Co., Ltd.
-
Global Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Treatment-Naïve Patients with CLL/SLL Approved by the China CDE
10/13/2023
Ascentage Pharma announced that the Center for Drug Evaluation of China NMPA has approved a global pivotal registrational Phase III study designed to evaluate a key drug candidate in Ascentage Pharma's pipeline, Bcl-2 inhibitor APG-2575, in combination with the Bruton's tyrosine kinase inhibitor acalabrutinib.
-
Ascentage Pharma Announces 2023 Interim Results Highlighting Significant Increase in Sales and Clearance for Global Registrational Phase III Trial
8/21/2023
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its 2023 interim results.
-
Ascentage Pharma Received Clearance from U.S. FDA to Proceed with Global Registrational Phase III Clinical Trial for Lisaftoclax (APG-2575) in Previously Treated Patients with CLL/SLL
8/7/2023
Ascentage Pharma announced that lisaftoclax, a novel Bcl-2 inhibitor and one of the company's core assets, has been cleared by the US Food and Drug Administration to enter a global registrational Phase III study for treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who were BTKi previously treated.